Global Hemato Oncology Testing Market - 2023-2030

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,350	195 Pages	DataM Intelligence 4Market Research LLP	March, 2023	DTAM17834617

Best Price Guarantee
Price	from $4,350
Length	195 Pages
Publisher	DataM Intelligence 4Market Research LLP
Published Date	March, 2023
SKU	DTAM17834617

Global Hemato Oncology Testing Market - 2023-2030

Market Overview
The global hemato oncology Testing market reached US$ 280 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 620 million by 2030. The market is growing at a CAGR of 4.8% during the forecast period (2023-2030).

Hematologic oncology integrates two fields of medicine: hematology, the study of the blood, and oncology, the study of cancer. Hematologic oncologists are trained in diagnosing, treating, and preventing blood cancers and blood-related disorders. The field of haemato-oncology deals with the treatment of blood and related cancers.

Market Dynamics
Technological advancements in drug diagnosis and services
The growing advancements and new technologically advanced product introductions into the market are boosting the global hemato oncology testing market growth. For instance, in August 2022, Thermo Fisher Scientific introduced CE-IVD (IVDD) next-generation sequencing test and analysis software to extend access to precision oncology biomarker testing. Likewise, in June 2022, Burning Rock Biotech Limited was granted a CE marking for its OverC multi-cancer estimation blood test. OverC Multi-Cancer Detection Blood Test is a qualitative next-generation sequencing (NGS)-based in vitro diagnostic device. Similarly, in November 2021, SAN DIEGO and Genetic Alliance created the iHope Genetic Health program targeted at delivering whole-genome sequencing access (WGS) to tens of thousands of individuals all over the globe affected by genetic disease.

Growing awareness regarding personalized medicines is presenting the market with lucrative growth opportunities.
Personalized medicine is a blossoming practice of medicine that employs an individual's genetic profile to direct decisions formed for the prevention, diagnosis, and treatment of the disorder. Knowledge of a patient's genetic profile can aid physicians to choose the most accurate medication or therapy and administer it utilizing the appropriate dose or regimen. The growing awareness and efforts to implement personalized medicine are providing the market with very lucrative growth opportunities For instance, in January 2021, the FDA declared its involvement in providing physicians with knowledge on the designing of novel therapies as the role of personalized medicine keeps on expanding. Furthermore, the European Cancer Patient Coalition (ECPC) lead the first Personalized Medicine Awareness Month throughout November, the ECPC promoted the significance of access to cancer molecular testing during a month-long advocacy campaign called, Personalized Medicine Awareness Month: Cracking the Cancer Code.

Segment Analysis
The global hemato oncology testing market is segmented based on Product & Services, Cancer Type, Technology, and region.

Owing to growing new technological advancements, product launches, and recent development
The increasing market developments such as collaborations, and product launches among others are boosting the services segment growth during the forecast period. For instance, in August 2020 Thermo Fisher Scientific introduced hematology-oncology assays for the Ion Torrent Genexus System. Also, in May 2022, the Qatar Foundation (QF) division of the Qatar Genome Program (QGP), and Thermo Fisher Scientific partnered for the advancement of genomic research and clinical applications of predictive genomics in Qatar as a step in the direction of expanding the benefits of precision medicine all over the Arab populations worldwide. Similarly, in August 2022, Mount Sinai Health System and the Icahn School of Medicine introduced a new human genome sequencing research project known as the Mount Sinai Million Health Discoveries Program with the Regeneron Genetics Center (RGC). Thus, the mentioned data indicates that the services segment will dominate the global hemato-oncology testing market throughout the forecast period.

Geographical Penetration
The strong presence of major players and increased awareness about the use of eco-friendly products
North America dominates the global hemato oncology testing market during the forecast period, owing to the growing cases of leukemia, better reimbursement policies, and the presence of key market players holding the majority of the market in this region. For instance, according to the Canada Cancer Society report that there were over 6,700 Canadians diagnosed with leukemia, of which around 4,000 were men and about 2,700 were women in 2021. Also, the American Cancer Society documented that approximately 60,650 new cases of leukemia and 20,050 new cases of acute myeloid leukemia (AML) were diagnosed in the United States in 2022. Also, acute myeloid leukemia (AML) made up only about 1% of all cancers. Furthermore, Abbott Laboratories, Thermofisher Scientific, and Illumina are among the key market players holding the majority of market share based in the North American region ensuring the dominance of the region over the global market.

Competitive Landscape
The major global players include F. Hoffman-La Roche Ltd., Abbott Laboratories, Qiagen N.V., Thermo Fisher Scientific, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., ICON PLC, Archerdx, Inc., Invivoscribe, Inc., and Adaptive Biotechnologies.

COVID-19 Impact Analysis
By Type of Product & Service
• Instruments
• Reagents & Consumables
• Services
By Technology
• PCR (Polymerase Chain Reaction)
• IHC (immunohistochemical)
• NGS (Next-Generation Sequencing)
• Cytogenetics
• Others
By Cancer Type
• Leukemia
Acute Myeloid Leukemia
Acute Lymphocytic Leukemia
Others
• Lymphoma
• Multiple myelomas
• Others
By End-user
• Clinical Laboratories
• Hospitals
• Academic & Research Institutes
• Others
By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Russia
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• In 2022, the US FDA granted approval to F. Hoffmann-La Roche Ltd. (Switzerland) for its cobras EZH2 mutation test as a companion diagnostic for patients with follicular lymphoma.
• In 2020, F. Hoffmann-La Roche Ltd. (Switzerland) and Illumina Inc. (US) formed a 15-year non-exclusive collaboration with Illumina to extend the adoption of NGS-based testing in oncology.
• In 2021, QIAGEN N.V. (Germany) and Denovo Biopharma LLC (US) formed a partnership to design a blood-based companion diagnostic (CDx) test for the treatment of diffuse large B-cell lymphoma (DLBCL), one of the most typical lymphoid cancers.

Why Purchase the Report?
• To visualize the global Hemato Oncology Testing- market segmentation based on product, application and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of Hemato Oncology Testing market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global Hemato Oncology Testing market report would provide approximately 69 tables, 71 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

1. Methodology and Scope: 1.1. Research Methodology; 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary: 3.1. Snippet by Type of Products & Services; 3.2. Snippet by Technology; 3.3. Snippet by Type of cancer; 3.4. Snippet by End-user; 3.5. Snippet by Region
4. Dynamics: 4.1. Impacting Factors; 4.1.1. Drivers; 4.1.1.1. Technological Advancements In Drug Diagnosis And Services; 4.1.1.2. Increasing Prevalence of Hematologic Cancer Globally; 4.1.1.3. XX; 4.1.2. Restraints; 4.1.2.1. Unfavorable And Uncertain Reimbursement Scenario; 4.1.2.2. XX; 4.1.3. Opportunity; 4.1.3.1. XX; 4.1.4. Impact Analysis
5. Industry Analysis: 5.1. Porter's Five Forces Analysis; 5.2. Supply Chain Analysis; 5.3. Pricing Analysis; 5.4. Regulatory Analysis
6. COVID-19 Analysis: 6.1. Analysis of COVID-19; 6.1.1. Before COVID-19 Scenario; 6.1.2. Present COVID-19 Scenario; 6.1.3. Post COVID-19 or Future Scenario; 6.2. Pricing Dynamics Amid COVID-19; 6.3. Demand-Supply Spectrum; 6.4. Government Initiatives Related to the Market During Pandemic; 6.5. Manufacturers Strategic Initiatives; 6.6. Conclusion
7. By Type of Product & Service: 7.1. Introduction; 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service; 7.1.2. Market Attractiveness Index, By Type of Product & Service; 7.2. Instruments; 7.2.1. Introduction; 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 7.3. Reagents & Consumables; 7.4. Services
8. By Technology: 8.1. Introduction; 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology; 8.1.2. Market Attractiveness Index, By Technology; 8.2. PCR (Polymerase Chain Reaction) *; 8.2.1. Introduction; 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 8.3. IHC (immunohistochemical); 8.4. NGS (Next-Generation Sequencing); 8.5. Cytogenetics; 8.6. Others
9. By Cancer Type: 9.1. Introduction; 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type; 9.1.2. Market Attractiveness Index, By Cancer Type; 9.2. Leukemia*; 9.2.1. Introduction; 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 9.2.3. Acute Myeloid Leukemia; 9.2.4. Acute Lymphocytic Leukemia; 9.2.5. Others; 9.3. Lymphoma; 9.4. Multiple myelomas; 9.5. Others
10. By End-user: 10.1. Introduction; 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user; 10.1.2. Market Attractiveness Index, By End-user; 10.2. Clinical Laboratories*; 10.2.1. Introduction; 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%); 10.3. Hospitals; 10.4. Academic & Research Institutes; 10.5. Others
11. By Region: 11.1. Introduction; 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region; 11.1.2. Market Attractiveness Index, By Region; 11.2. North America; 11.2.1. Introduction; 11.2.2. Key Region-Specific Dynamics; 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type of Product & Service; 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology; 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type; 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user; 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 11.2.7.1. U.S.; 11.2.7.2. Canada; 11.2.7.3. Mexico; 11.3. Europe; 11.3.1. Introduction; 11.3.2. Key Region-Specific Dynamics; 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology; 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type; 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user; 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 11.3.6.1. Germany; 11.3.6.2. UK; 11.3.6.3. France; 11.3.6.4. Italy; 11.3.6.5. Russia; 11.3.6.6. Rest of Europe; 11.4. South America; 11.4.1. Introduction; 11.4.2. Key Region-Specific Dynamics; 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology; 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type; 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user; 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 11.4.6.1. Brazil; 11.4.6.2. Argentina; 11.4.6.3. Rest of South America; 11.5. Asia-Pacific; 11.5.1. Introduction; 11.5.2. Key Region-Specific Dynamics; 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology; 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type; 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user; 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country; 11.5.6.1. China; 11.5.6.2. India; 11.5.6.3. Japan; 11.5.6.4. Australia; 11.5.6.5. Rest of Asia-Pacific; 11.6. Middle East and Africa; 11.6.1. Introduction; 11.6.2. Key Region-Specific Dynamics; 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology; 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Caner Type; 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
12. Competitive Landscape: 12.1. Competitive Scenario; 12.2. Market Positioning/Share Analysis; 12.3. Mergers and Acquisitions Analysis
13. Company Profiles: 13.1. F. Hoffman-La Roche Ltd.*; 13.1.1. Company Overview; 13.1.2. Product Portfolio and Description; 13.1.3. Financial Overview; 13.1.4. Key Developments; 13.2. Abbott Laboratories; 13.3. Qiagen N.V.; 13.4. Thermo Fisher Scientific, Inc.; 13.5. Illumina, Inc.; 13.6. Bio-Rad Laboratories, Inc.; 13.7. ICON PLC; 13.8. Archerdx, Inc.; 13.9. Invivoscribe, Inc.; 13.10. Adaptive Biotechnologies; LIST NOT EXHAUSTIVE
14. Appendix: 14.1. About Us and Services; 14.2. Contact Us